Abstract:This study examines the role of new genome editing tools in treating retinitis pigmentosa (RP), particularly focusing on the Pde6a‐D670G mutation. Highlighting the potential of engineered base editing (BE) and prime editing (PE), it demonstrates how these advanced techniques can precisely correct the point mutation in Pde6a mouse model, effectively restoring retinal function. Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMP‐specific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adeno‐associated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proof‐of‐concept demonstration for the treatment of Pde6a‐related retinal degeneration using BE and PE systems.

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver

Efficient prime editing in mouse brain, liver and heart with dual AAVs

Improved split prime editors enable efficient in vivo genome editing

Cost-effective Generation of A-to-G Mutant Mice by Zygote Electroporation of Adenine Base Editor Ribonucleoproteins.

Improved Prime Editors Enable Pathogenic Allele Correction and Cancer Modelling in Adult Mice

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa

Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

A split prime editor with untethered reverse transcriptase and circular RNA template

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

In vivo prime editing of a metabolic liver disease in mice

Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo

Development Of Highly Efficient Dual-Aav Split Adenosine Base Editor For In Vivo Gene Therapy

In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration

Treatment of a genetic liver disease in mice through transient prime editor expression

Enrichment of Allelic Editing Outcomes by Prime Editing in Induced Pluripotent Stem Cells

In vivo base editing rescues photoreceptors in a mouse model of retinitis pigmentosa

Mini-PE, a prime editor with compact Cas9 and truncated reverse transcriptase

Enrichment of allelic editing outcomes by Prime Editing in iPS cells